EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies

EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging

Read more at globenewswire.com